The massive biopharmaceutical company AstraZeneca has declared that it will be launching cutting-edge lung cancer diagnostic testing in Kenya and Nigeria.
According to AstraZeneca, the Federal Ministry of Health in Nigeria and Moi Teaching and Referral Hospital (MTRH) are working together to improve the infrastructure for molecular testing.
With this year’s theme, “United by Unique,” AstraZeneca underlined its dedication to promoting early detection, cutting-edge therapies, and comprehensive patient care in honor of World Cancer Day 2025.
In a statement, the company stated, “This theme emphasizes the value of patient-centered care, creative methods to enhance results, and the strength of teamwork in advancing cancer care.”
Project Flamingo, an AI-driven healthcare breakthrough in South Africa, was launched by AstraZeneca and Medsol AI Solutions. It improves early breast cancer identification in underserved populations by enabling real-time breast ultrasound images and predictive analysis.
According to AstraZeneca, the AI-powered app has shown 97.6% accuracy in detecting cancers, assisting with early detection initiatives and relieving load on public health systems.
Khomotso Mashilane, Medical Director of AstraZeneca, stated, “We are dedicated to advancing innovation in oncology care through early detection and precision diagnostics.”
He continued by saying that AstraZeneca wants to enable patients and healthcare professionals to improve outcomes and quality of life by utilizing cutting-edge technologies, creating patient-centered solutions, and cultivating meaningful collaborations.
“We honor each patient’s individual journey on this World Cancer Day and reaffirm our commitment to advancing science and providing meaningful care,” he said.
Launched in Kenya in collaboration with the Ministry of Health and other important partners, AstraZeneca’s Cancer Care Africa program aims to expand access to cutting-edge cancer medicines, empower patients, and improve diagnostics.
Cancer continues to be a major cause of death worldwide, with worsening results due to delayed diagnosis and restricted access to care.
According to WHO forecasts, the cancer death rate in sub-Saharan Africa may almost quadruple by 2030.
With its headquarters in Cambridge, UK, AstraZeneca has operations in more than 100 nations, and millions of people use its medications globally.
Finding, creating, and marketing prescription drugs in the fields of cancer, rare disorders, and biopharmaceuticals—such as those related to the heart, kidneys, metabolism, respiratory system, and immune system—are the main priorities of AstraZeneca.
ALSO READ:
NLC Stops Protesting Telecom Rate Hikes While FG Arranges A Review Panel.
